Nuvalent, Inc.

Ownership Transactions Reported by 20 Insiders

Symbol
NUVL on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Broadway, 14 Th Floor, Cambridge, MA

Insiders trading volume in the past year

Nuvalent, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
James E. Flynn Director, * Director by deputization, 10%+ Owner $1.76B -$196M -10% Oct 22, 2024
Matthew Shair Director $161M -$31.2M -16.3% Nov 25, 2024
Andrew Hack Director $128M -$174M -57.7% Dec 11, 2024
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10%+ Owner $68.3M Aug 2, 2021
Deerfield Partners, L.P. Director, Director by Deputization, 10%+ Owner $49.5M Nov 3, 2022
Christopher Durant Turner Chief Medical Officer $3.64M Jan 5, 2024
Deborah Ann Miller Chief Legal Officer $3.4M -$5.61M -62.3% Sep 16, 2024
Darlene Noci Chief Development Officer $3M -$3.69M -55.2% Nov 1, 2024
Alexandra Balcom Chief Financial Officer $324K -$5.25M -94.2% Dec 17, 2024
Grant C. Bogle Director $308K Dec 5, 2024
Emily Conley Director $213K -$2.83M -93% Aug 23, 2024
Michael L. Meyers Director $206K Jun 12, 2024
Cameron Wheeler Director $206K Jun 12, 2024
Sapna Srivastava Director $206K Jun 12, 2024
Joseph Pearlberg Director $206K Jun 12, 2024
Anna Protopapas Director $206K Jun 12, 2024
Dwight Gary Gilliland Director $206K Jun 12, 2024
James Richard Porter President and CEO, Director $137K -$7.47M -98.2% Dec 19, 2024
Henry E. Pelish Chief Scientific Officer $38K -$4.14M -99.1% Dec 16, 2024
Robert Bowers Jackson Director Jul 28, 2021

Recent Insider Transactions by Companies or Individuals for Nuvalent, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.